Symbols / RARE Stock $23.87 +2.14% Ultragenyx Pharmaceutical Inc.

Healthcare • Biotechnology • United States • NMS
RARE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Emil D. Kakkis M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 2.35B
Enterprise Value 3.09B
Income -609.00M
Sales 670.00M
FCF (ttm) -219.09M
Book/sh -0.83
Cash/sh 4.21
Employees 1,371
Insider 10d —
IPO Jan 31, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 24.73
PEG —
P/S 3.51
P/B -28.76
P/C —
EV/EBITDA -6.21
EV/Sales 4.61
Quick Ratio 1.65
Current Ratio 2.02
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -6.10
EPS next Y 0.97
EPS Growth —
Revenue Growth -2.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-05
ROA -25.45%
ROE —
ROIC —
Gross Margin -28.06%
Oper. Margin -102.21%
Profit Margin -90.90%
Shs Outstand 98.49M
Shs Float 94.63M
Insider Own 3.43%
Instit Own 104.07%
Short Float 14.38%
Short Ratio 7.48
Short Interest 13.67M
52W High 42.37
vs 52W High -43.66%
52W Low 18.29
vs 52W Low 30.51%
Beta 0.39
Impl. Vol. 57.79%
Rel Volume 0.41
Avg Volume 1.89M
Volume 764.73K
Target (mean) $51.42
Tgt Median $48.00
Tgt Low $25.00
Tgt High $84.00
# Analysts 19
Recom Strong_buy
Prev Close $23.37
Price $23.87
Change 2.14%
About

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$51.42
Mean price target
2. Current target
$23.87
Latest analyst target
3. DCF / Fair value
$-40.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$23.87
Low
$25.00
High
$84.00
Mean
$51.42

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-10-22 reit Cantor Fitzgerald Overweight → Overweight $116
2024-10-21 main TD Cowen Buy → Buy $73
2024-10-01 reit Cantor Fitzgerald Overweight → Overweight $116
2024-09-26 reit RBC Capital Outperform → Outperform $77
2024-09-20 reit Cantor Fitzgerald Overweight → Overweight $116
2024-09-16 reit Cantor Fitzgerald Overweight → Overweight $116
2024-08-05 main Barclays Overweight → Overweight $81
2024-08-02 main Wells Fargo Overweight → Overweight $75
2024-08-02 main Goldman Sachs Buy → Buy $76
2024-08-02 main Cantor Fitzgerald Overweight → Overweight $116
2024-08-02 main Wedbush Neutral → Neutral $46
2024-07-23 main Canaccord Genuity Buy → Buy $111
2024-07-22 reit Cantor Fitzgerald Overweight → Overweight $115
2024-07-18 reit Wedbush Neutral → Neutral $45
2024-06-12 reit Cantor Fitzgerald Overweight → Overweight $115
2024-06-06 up Goldman Sachs Neutral → Buy $67
2024-05-31 main Wedbush Neutral → Neutral $48
2024-05-31 main B of A Securities Buy → Buy $76
2024-05-31 main Canaccord Genuity Buy → Buy $111
2024-05-31 main Cantor Fitzgerald Overweight → Overweight $115
News
RSS: Latest RARE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-18 SULIMAN SHEHNAAZ Director — 5,740 $25.12 $144,189
2026-05-14 RAY AMRIT Director — 7,751 $0.00 $0
2026-05-14 SULIMAN SHEHNAAZ Director — 7,751 $0.00 $0
2026-05-14 SANDERS CORAZON CORSEE D Director — 7,751 $0.00 $0
2026-05-05 CROMBEZ ERIC M.D. Officer — 344 $24.96 $8,586
2026-05-01 HORN HOWARD Chief Financial Officer — 4,683 $24.90 $116,607
2026-04-22 HUIZENGA THEODORE ALAN Officer — 20,241 $0.00 $0
2026-04-16 KAKKIS EMIL D Chief Executive Officer — 76,745 $0.00 $0
2026-04-16 CROMBEZ ERIC M.D. Officer — 34,674 $0.00 $0
2026-04-16 PARSCHAUER KARAH HERDMAN Officer — 28,895 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
673.00
+20.18%
560.00
+29.03%
434.00
+19.45%
363.33
Operating Revenue
673.00
+20.18%
560.00
+29.03%
434.00
+19.45%
363.33
Cost Of Revenue
109.00
+41.56%
77.00
+71.11%
45.00
+58.90%
28.32
Reconciled Cost Of Revenue
109.00
+41.56%
77.00
+71.11%
45.00
+58.90%
28.32
Gross Profit
564.00
+16.77%
483.00
+24.16%
389.00
+16.12%
335.01
Operating Expense
1,099.00
+7.85%
1,019.00
+6.37%
958.00
-2.64%
983.93
Research And Development
750.00
+7.45%
698.00
+7.72%
648.00
-8.19%
705.79
Selling General And Administration
349.00
+8.72%
321.00
+3.55%
310.00
+11.46%
278.14
Total Expenses
1,208.00
+10.22%
1,096.00
+9.27%
1,003.00
-0.91%
1,012.25
Operating Income
-535.00
+0.19%
-536.00
+5.80%
-569.00
+12.32%
-648.92
Total Operating Income As Reported
-535.00
+0.19%
-536.00
+5.80%
-569.00
+12.32%
-648.92
EBITDA
-474.00
-1.28%
-468.00
+9.48%
-517.00
+19.28%
-640.49
Normalized EBITDA
-474.00
-1.28%
-468.00
+9.48%
-517.00
+16.77%
-621.19
Reconciled Depreciation
35.00
-2.78%
36.00
+38.46%
26.00
+42.70%
18.22
EBIT
-509.00
-0.99%
-504.00
+7.18%
-543.00
+17.57%
-658.71
Total Unusual Items
—
-1.11
-380.86%
0.40
+102.06%
-19.30
Total Unusual Items Excluding Goodwill
—
-1.11
-380.86%
0.40
+102.06%
-19.30
Net Income
-575.00
-1.05%
-569.00
+6.26%
-607.00
+14.20%
-707.42
Pretax Income
-571.00
-0.71%
-567.00
+6.90%
-609.00
+13.21%
-701.73
Net Non Operating Interest Income Expense
-37.00
-42.31%
-26.00
+33.33%
-39.00
-22.10%
-31.94
Interest Expense Non Operating
62.00
-1.59%
63.00
-4.55%
66.00
+53.43%
43.02
Net Interest Income
-37.00
-42.31%
-26.00
+33.33%
-39.00
-22.10%
-31.94
Interest Expense
62.00
-1.59%
63.00
-4.55%
66.00
+53.43%
43.02
Interest Income Non Operating
25.00
-32.43%
37.00
+37.04%
27.00
+143.81%
11.07
Interest Income
25.00
-32.43%
37.00
+37.04%
27.00
+143.81%
11.07
Other Income Expense
1.00
+120.00%
-5.00
-400.00%
-1.00
+95.21%
-20.86
Other Non Operating Income Expenses
1.00
+120.00%
-5.00
-400.00%
-1.00
+36.14%
-1.57
Gain On Sale Of Security
—
-1.11
-380.86%
0.40
+102.06%
-19.30
Tax Provision
4.00
+100.00%
2.00
+200.00%
-2.00
-135.11%
5.70
Tax Rate For Calcs
0.00
+0.00%
0.00
+6294.64%
0.00
-98.44%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-4.05
Net Income Including Noncontrolling Interests
-575.00
-1.05%
-569.00
+6.26%
-607.00
+14.20%
-707.42
Net Income From Continuing Operation Net Minority Interest
-575.00
-1.05%
-569.00
+6.26%
-607.00
+14.20%
-707.42
Net Income From Continuing And Discontinued Operation
-575.00
-1.05%
-569.00
+6.26%
-607.00
+14.20%
-707.42
Net Income Continuous Operations
-575.00
-1.05%
-569.00
+6.26%
-607.00
+14.20%
-707.42
Normalized Income
-575.00
-1.05%
-569.00
+6.26%
-607.00
+12.31%
-692.17
Net Income Common Stockholders
-575.00
-1.05%
-569.00
+6.26%
-607.00
+14.20%
-707.42
Diluted EPS
-5.83
+7.31%
-6.29
+23.76%
-8.25
+18.48%
-10.12
Basic EPS
-5.83
+7.31%
-6.29
+23.76%
-8.25
+18.48%
-10.12
Basic Average Shares
98.60
+8.90%
90.54
+23.11%
73.54
+5.19%
69.91
Diluted Average Shares
98.60
+8.90%
90.54
+23.11%
73.54
+5.19%
69.91
Diluted NI Availto Com Stockholders
-575.00
-1.05%
-569.00
+6.26%
-607.00
+14.20%
-707.42
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
1,532.00
+1.93%
1,503.00
+0.80%
1,491.01
Current Assets
951.00
+16.40%
817.00
+11.58%
732.18
Cash Cash Equivalents And Short Term Investments
680.00
+11.48%
610.00
+5.68%
577.21
Cash And Cash Equivalents
421.00
+141.95%
174.00
-18.53%
213.58
Other Short Term Investments
259.00
-40.60%
436.00
+19.90%
363.62
Receivables
158.00
+29.51%
122.00
+66.24%
73.39
Accounts Receivable
158.00
+29.51%
122.00
+66.24%
73.39
Inventory
52.00
+15.56%
45.00
+32.47%
33.97
Work In Process
27.00
+22.73%
22.00
+16.66%
18.86
Finished Goods
25.00
+8.70%
23.00
+52.22%
15.11
Prepaid Assets
—
—
—
Other Current Assets
61.00
+52.50%
40.00
-15.99%
47.62
Total Non Current Assets
581.00
-15.31%
686.00
-9.60%
758.83
Net PPE
244.00
-8.27%
266.00
-8.45%
290.57
Gross PPE
380.00
+0.53%
378.00
+1.08%
373.97
Accumulated Depreciation
-136.00
-21.43%
-112.00
-34.29%
-83.40
Properties
0.00
0.00
0.00
Land And Improvements
17.00
+0.00%
17.00
+2.29%
16.62
Buildings And Improvements
182.00
+0.00%
182.00
+0.36%
181.36
Machinery Furniture Equipment
23.00
+4.55%
22.00
-2.72%
22.61
Construction In Progress
—
—
0.87
Other Properties
103.00
+4.04%
99.00
+4.55%
94.69
Leases
55.00
-5.17%
58.00
-1.16%
58.68
Goodwill And Other Intangible Assets
220.00
-0.90%
222.00
+5.37%
210.68
Goodwill
44.00
+0.00%
44.00
-0.91%
44.41
Other Intangible Assets
176.00
-1.12%
178.00
+7.05%
166.27
Investments And Advances
57.00
-57.78%
135.00
-32.47%
199.90
Long Term Equity Investment
—
—
—
Other Investments
—
—
—
Other Non Current Assets
60.00
-4.76%
63.00
+9.21%
57.69
Total Liabilities Net Minority Interest
1,605.00
+29.33%
1,241.00
+2.09%
1,215.60
Current Liabilities
384.00
+11.63%
344.00
+22.67%
280.44
Payables And Accrued Expenses
239.00
-3.24%
247.00
+11.48%
221.57
Payables
31.00
-20.51%
39.00
-7.39%
42.11
Accounts Payable
31.00
-20.51%
39.00
-7.39%
42.11
Current Accrued Expenses
208.00
+0.00%
208.00
+15.91%
179.46
Current Debt And Capital Lease Obligation
12.00
+20.00%
10.00
-20.60%
12.60
Current Capital Lease Obligation
12.00
+20.00%
10.00
-20.60%
12.60
Current Deferred Liabilities
—
—
0.00
Current Deferred Revenue
—
—
0.00
Other Current Liabilities
76.00
+40.74%
54.00
+84.67%
29.24
Total Non Current Liabilities Net Minority Interest
1,221.00
+36.12%
897.00
-4.08%
935.16
Liabilities Heldfor Sale Non Current
1,147.00
+39.88%
820.00
-4.91%
862.33
Long Term Debt And Capital Lease Obligation
24.00
-20.00%
30.00
-1.88%
30.57
Long Term Capital Lease Obligation
24.00
-20.00%
30.00
-1.88%
30.57
Non Current Deferred Liabilities
30.00
+0.00%
30.00
-0.19%
30.06
Non Current Deferred Revenue
—
—
—
Non Current Deferred Taxes Liabilities
30.00
+0.00%
30.00
-0.19%
30.06
Other Non Current Liabilities
20.00
+17.65%
17.00
+39.29%
12.21
Stockholders Equity
-80.00
-131.37%
255.00
-7.41%
275.41
Common Stock Equity
-80.00
-131.37%
255.00
-7.41%
275.41
Capital Stock
0.00
0.00
-100.00%
0.08
Common Stock
0.00
0.00
-100.00%
0.08
Preferred Stock
0.00
0.00
0.00
Share Issued
96.65
+4.43%
92.55
+12.43%
82.33
Ordinary Shares Number
96.48
+4.32%
92.48
+12.35%
82.32
Treasury Shares Number
0.17
+148.05%
0.07
+629.75%
0.01
Additional Paid In Capital
4,451.00
+5.65%
4,213.00
+15.04%
3,662.35
Retained Earnings
-4,532.00
-14.53%
-3,957.00
-16.81%
-3,387.66
Gains Losses Not Affecting Retained Earnings
1.00
+200.00%
-1.00
-254.56%
0.65
Treasury Stock
8.00
+100.00%
4.00
+825.93%
0.43
Minority Interest
7.00
+0.00%
7.00
0.00
Other Equity Adjustments
1.00
+200.00%
-1.00
—
Total Equity Gross Minority Interest
-73.00
-127.86%
262.00
-4.87%
275.41
Total Capitalization
-80.00
-131.37%
255.00
-7.41%
275.41
Working Capital
567.00
+19.87%
473.00
+4.70%
451.75
Invested Capital
-80.00
-131.37%
255.00
-7.41%
275.41
Total Debt
36.00
-10.00%
40.00
-7.34%
43.17
Capital Lease Obligations
36.00
-10.00%
40.00
-7.34%
43.17
Net Tangible Assets
-300.00
-1009.09%
33.00
-49.02%
64.74
Tangible Book Value
-300.00
-1009.09%
33.00
-49.02%
64.74
Available For Sale Securities
57.00
-57.78%
135.00
-32.47%
199.90
Current Provisions
57.00
+72.73%
33.00
+93.79%
17.03
Foreign Currency Translation Adjustments
—
-1.65
-172.28%
-0.61
Investmentin Financial Assets
57.00
-57.78%
135.00
-32.47%
199.90
Other Equity Interest
8.00
+100.00%
4.00
+825.93%
0.43
Unrealized Gain Loss
—
1.01
-19.63%
1.25
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-466.00
-12.56%
-414.00
+12.84%
-475.00
-24.85%
-380.46
Cash Flow From Continuing Operating Activities
-466.00
-12.56%
-414.00
+12.84%
-475.00
-24.85%
-380.46
Net Income From Continuing Operations
-575.00
-1.05%
-569.00
+6.26%
-607.00
+14.20%
-707.42
Depreciation Amortization Depletion
35.00
-2.78%
36.00
+38.46%
26.00
+42.70%
18.22
Depreciation And Amortization
35.00
-2.78%
36.00
+38.46%
26.00
+42.70%
18.22
Other Non Cash Items
-52.00
-30.00%
-40.00
-3673.58%
-1.06
-101.10%
96.13
Stock Based Compensation
153.00
-3.16%
158.00
+17.04%
135.00
+3.55%
130.38
Unrealized Gain Loss On Investment Securities
—
1.11
+380.86%
-0.40
-102.06%
19.30
Change In Working Capital
-23.00
-264.29%
14.00
+187.50%
-16.00
-126.56%
60.23
Change In Receivables
-31.00
+8.82%
-34.00
-47.83%
-23.00
-90.59%
-12.07
Changes In Account Receivables
-31.00
+8.82%
-34.00
-47.83%
-23.00
-90.59%
-12.07
Change In Inventory
-6.00
+45.45%
-11.00
-57.14%
-7.00
+27.84%
-9.70
Change In Prepaid Assets
-10.00
-183.33%
12.00
-20.00%
15.00
+294.94%
3.80
Change In Payables And Accrued Expense
24.00
-48.94%
47.00
+4800.00%
-1.00
-101.25%
79.84
Change In Payable
24.00
-48.94%
47.00
+4800.00%
-1.00
-101.25%
79.84
Change In Account Payable
24.00
-48.94%
47.00
+4800.00%
-1.00
-101.25%
79.84
Change In Other Working Capital
—
—
-3.10
-89.02%
-1.64
Investing Cash Flow
236.00
+1411.11%
-18.00
-110.71%
168.00
+157.60%
-291.65
Cash Flow From Continuing Investing Activities
236.00
+1411.11%
-18.00
-110.71%
168.00
+157.60%
-291.65
Net PPE Purchase And Sale
-6.00
+14.29%
-7.00
+84.09%
-44.00
+62.11%
-116.12
Purchase Of PPE
-6.00
+14.29%
-7.00
+84.09%
-44.00
+62.11%
-116.12
Capital Expenditure
-21.00
-5.00%
-20.00
+57.45%
-47.00
+67.84%
-146.12
Net Investment Purchase And Sale
258.00
+6350.00%
4.00
-98.19%
221.00
+417.26%
-69.66
Purchase Of Investment
-186.00
+54.52%
-409.00
+22.24%
-526.00
+14.43%
-614.74
Sale Of Investment
444.00
+7.51%
413.00
-44.71%
747.00
+37.05%
545.08
Net Business Purchase And Sale
—
0.00
0.00
+100.00%
-75.03
Purchase Of Business
—
0.00
0.00
+100.00%
-75.03
Net Intangibles Purchase And Sale
-15.00
-15.38%
-13.00
-333.33%
-3.00
+90.00%
-30.00
Purchase Of Intangibles
-15.00
-15.38%
-13.00
-333.33%
-3.00
+90.00%
-30.00
Net Other Investing Changes
-1.00
+50.00%
-2.00
+66.67%
-6.00
-610.90%
-0.84
Financing Cash Flow
478.00
+19.80%
399.00
+2.84%
388.00
-22.59%
501.21
Cash Flow From Continuing Financing Activities
478.00
+19.80%
399.00
+2.84%
388.00
-22.59%
501.21
Net Common Stock Issuance
86.00
-78.06%
392.00
+1.29%
387.00
0.00
Proceeds From Stock Option Exercised
—
11.26
+33.78%
8.41
-22.18%
10.81
Net Other Financing Charges
392.00
+5500.00%
7.00
+600.00%
1.00
-99.80%
490.39
Changes In Cash
248.00
+851.52%
-33.00
-140.74%
81.00
+147.39%
-170.91
Effect Of Exchange Rate Changes
4.00
+300.00%
-2.00
0.00
+100.00%
-1.07
Beginning Cash Position
184.00
-15.98%
219.00
+58.70%
138.00
-55.42%
309.58
End Cash Position
436.00
+136.96%
184.00
-15.98%
219.00
+59.16%
137.60
Free Cash Flow
-487.00
-12.21%
-434.00
+16.86%
-522.00
+0.87%
-526.59
Amortization Of Securities
-4.00
+69.23%
-13.00
+0.00%
-13.00
-581.66%
2.70
Common Stock Issuance
86.00
-78.06%
392.00
+1.29%
387.00
0.00
Issuance Of Capital Stock
86.00
-78.06%
392.00
+1.29%
387.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category